Anti-XIAP antibody [EPR22189-113],Abcam,AB229050

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

WB

Platform ID

BAB078227933

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-XIAP antibody [EPR22189-113]
Cat. No.AB229050
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationWB
ClonalityMonoclonal
Clone NumberEPR22189-113
Concentration0.532 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis (PubMed : 11257230, PubMed : 11257231, PubMed : 11447297, PubMed : 12121969, PubMed : 12620238, PubMed : 17560374, PubMed : 17967870, PubMed : 19473982, PubMed : 20154138, PubMed : 22103349, PubMed : 9230442). Acts as a direct caspase inhibitor (PubMed : 11257230, PubMed : 11257231, PubMed : 12620238). Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry (PubMed : 11257230, PubMed : 11257231, PubMed : 16352606, PubMed : 16916640). Inactivates CASP9 by keeping it in a monomeric, inactive state (PubMed : 12620238). Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include : RIPK1, RIPK2, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS, PTEN and BIRC5/survivin (PubMed : 17560374, PubMed : 17967870, PubMed : 19473982, PubMed : 20154138, PubMed : 22103349, PubMed : 22607974, PubMed : 29452636, PubMed : 30026309). Acts as an important regulator of innate immunity by mediating 'Lys-63'-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling (PubMed : 19667203, PubMed : 22607974, PubMed : 29452636, PubMed : 30026309). 'Lys-63'-linked polyubiquitination of RIPK2 also promotes recruitment of the LUBAC complex to RIPK2 (PubMed : 22607974, PubMed : 29452636). Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation (PubMed : 17560374). Ubiquitination of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation (PubMed : 20154138). Ubiquitination of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation (PubMed : 17967870, PubMed : 22103349). Plays a role in copper homeostasis by ubiquitinating COMMD1 and promoting its proteasomal degradation (PubMed : 14685266). Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation (PubMed : 21145488). Ubiquitinates and therefore mediates the proteasomal degradation of BCL2 in response to apoptosis (PubMed : 29020630). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner (PubMed : 22095281). Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8 (PubMed : 22095281). Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES (PubMed : 22304967). Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program (PubMed : 22304967). See full target information XIAP

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.